BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Quizartinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Quizartinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03793478-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Quizartinib: Phase 1/2 readout est. (NCT03793478)
DESCRIPTION:Quizartinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Safet
 y and Efficacy of Quizartinib in Children and Young Adults With Acute Myel
 oid Leukemia (AML)\, a Cancer of the Blood\nEstimated primary completion: 
 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/quizartin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3793478
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548710-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Quizartinib: Phase 2 readout est. (NCT07548710)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study o
 f SA+X in the Treatment of Newly Diagnosed AML\nEstimated primary completi
 on: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/quiz
 artinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07548710
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04493138-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quizartinib: Phase 1/2 readout est. (NCT04493138)
DESCRIPTION:Quizartinib\, phase 1/2.\nStudy: Azacitidine and Quizartinib fo
 r the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloprolif
 erative Neoplasm With FLT3 or CBL Mutations\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qu
 izartinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04493138
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04047641-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quizartinib: Phase 1/2 readout est. (NCT04047641)
DESCRIPTION:Quizartinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Cladr
 ibine\, Idarubicin\, Cytarabine\, and Quizartinib in Treating Patients Wit
 h Newly Diagnosed\, Relapsed\, or Refractory Acute Myeloid Leukemia or Hig
 h-Risk Myelodysplastic Syndrome\nEstimated primary completion: 31 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/quizartinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT040476
 41
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04128748-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quizartinib: Phase 1/2 readout est. (NCT04128748)
DESCRIPTION:Quizartinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Lipos
 omal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatme
 nt of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/quizartinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04128748
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862517-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quizartinib: Phase 2 readout est. (NCT07862517)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing
  the Investigational Medication Combination of Azacitidine\, Venetoclax\, 
 and Quizartinib Compared to the Usual Treatment of Cytarabine\, Daunorubic
 in\, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leuke
 mia (A MyeloMATCH Treatment Trial)\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/quizartinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 62517
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03661307-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Quizartinib: Phase 1/2 readout est. (NCT03661307)
DESCRIPTION:Quizartinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Quiza
 rtinib\, Decitabine\, and Venetoclax in Treating Participants With Untreat
 ed or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrom
 e\nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/quizartinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03661307
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06262438-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Quizartinib: Phase 2 readout est. (NCT06262438)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: CHIP-AM
 L22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric F
 LT3-ITD+ and NPM1wt AML Patients\nEstimated primary completion: June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/quizartinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06262438
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824168-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Quizartinib: Phase 2 readout est. (NCT06824168)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Evaluat
 ion of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute
  Myeloid Leukemia Patients in Complete Remission\nEstimated primary comple
 tion: 6 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qu
 izartinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06824168
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769490-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Quizartinib: Phase 1 readout est. (NCT06769490)
DESCRIPTION:Quizartinib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Dose Es
 calation and Expansion of Ziftomenib in Combination With Quizartinib in Ac
 ute Myeloid Leukemia\nEstimated primary completion: 15 September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/quizartinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06769490
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Quizartinib: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOMA
 TCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment
  Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screeni
 ng Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/quizartinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735184-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Quizartinib: Phase 1 readout est. (NCT05735184)
DESCRIPTION:Quizartinib\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study
  to Investigate the Safety and Tolerability of Ziftomenib in Combination W
 ith Venetoclax/Azacitidine\, Venetoclax\, 7+3\, or 7+3+Quizartinib in Pati
 ents With AML\nEstimated primary completion: April 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/quizartinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05735184
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07478991-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Quizartinib: Phase 3 readout est. (NCT07478991)
DESCRIPTION:Quizartinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Azacyti
 dine\, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Pa
 tients (VENP-A-QUI)\nEstimated primary completion: April 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/quizartinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07478991
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578247-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20300626
DTEND;VALUE=DATE:20300627
SUMMARY:Quizartinib: Phase 3 readout est. (NCT06578247)
DESCRIPTION:Quizartinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Quizart
 inib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-IT
 D Negative AML\nEstimated primary completion: 26 June 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/quizartinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06578247
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949344-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Quizartinib: Phase 4 readout est. (NCT07949344)
DESCRIPTION:Quizartinib\, phase 4\, Acute Myeloid Leukemia.\nStudy: A Post-
 Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chin
 ese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal 
 Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML)\nEstimated 
 primary completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/quizartinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07949344
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07948122-2836@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Quizartinib: Phase 3 readout est. (NCT07948122)
DESCRIPTION:Quizartinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Prospec
 tive Evaluation of Response to Treatment in Younger Adult Patients (18-60 
 Years) With Acute Myeloid Leukemia (AML)\nEstimated primary completion: 31
  December 2035. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/quiza
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07948122
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
